Results 1 to 10 of about 1,834,303 (312)

Characteristics and Clinical Significance of Intestinal Microbiota in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus

open access: yesJournal of Diabetes Research, 2022
Background. Chronic hepatitis B cirrhosis is often accompanied by glucose metabolism disorder, and intestinal microbiota was closely related to both cirrhosis and diabetes.
Xiu Sun   +4 more
doaj   +1 more source

Fenofibrate in primary sclerosing cholangitis; a randomized, double‐blind, placebo‐controlled trial

open access: yesPharmacology Research & Perspectives, 2022
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with no medical treatment proven to improve survival and postpone liver transplantation. Previous studies have shown the effectiveness of fibrates in primary biliary cholangitis.
Behzad Hatami   +5 more
doaj   +1 more source

Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis

open access: yesMicroorganisms, 2021
Mucosal-associated invariant T (MAIT) cells are a subset of T lymphocytes expressing a semi-invariant T-cell receptor (TCR) present as TCR Vα7.2-Jα33 in humans and TCR Vα19-Jα33 in mice.
Yoseph Asmelash Gebru   +9 more
doaj   +1 more source

Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis [PDF]

open access: yes, 2020
Background A non-invasive method to grade the severity of steatohepatitis and liver fibrosis is magnetic resonance imaging (MRI) based corrected T1 (cT1).
Banerjee, R   +25 more
core   +3 more sources

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]

open access: yes, 2020
In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Alpini, Gianfranco   +4 more
core   +1 more source

Alcoholic liver disease [PDF]

open access: yesPostgraduate Medical Journal, 2000
Abstract Alcohol is a major cause of liver cirrhosis in the Western world and accounts for the majority of cases of liver cirrhosis seen in district general hospitals in the UK. The three most widely recognised forms of alcoholic liver disease are alcoholic fatty liver (steatosis), acute alcoholic hepatitis, and alcoholic cirrhosis.
K, Walsh, G, Alexander
openaire   +5 more sources

Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence

open access: yesBMC Cancer, 2023
Background Thermal therapy induces an immune response in patients with hepatocellular carcinoma (HCC), but the dynamic characteristics of the natural killer (NK) cell immune response post-thermal ablation remain unclear.
Hai-Yan Wang   +6 more
doaj   +1 more source

Antiviral Therapy for a Postpartum Flare in Women with Chronic HBV Infection Shortens the ALT Recovery Time and Reduces Hepatitis Re-Flare Rates within 4 years

open access: yesCanadian Journal of Gastroenterology and Hepatology, 2022
Background. Few studies explored whether anti-hepatitis B virus (HBV) therapy should be initiated during postpartum hepatitis flare. Aim. This study aimed to analyze the effect of anti-HBV therapy on postpartum hepatitis flare and evaluate the prognosis ...
Min Quan   +3 more
doaj   +1 more source

Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease

open access: yesCells, 2021
Nonalcoholic fatty liver disease (NAFLD) is one of the most common and increasing liver diseases worldwide. NAFLD is a term that involves a variety of conditions such as fatty liver, steatohepatitis, or fibrosis. Gut microbiota and its products have been
Eunju Park   +8 more
doaj   +1 more source

Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management

open access: yesViruses, 2019
It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional process ...
Alessandra Zannella   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy